relicpixant

**Relicpixant** is a potent, selective, orally active small molecule antagonist of the purinergic P2X3 receptor, a subtype of P2X receptors involved in ATP-mediated signaling. Developed initially by Wuhan Createrna Science and Technology Co., Ltd., it targets conditions associated with P2X3 hyperactivity, such as refractory chronic cough, by blocking ATP-induced activation of sensory neurons. Its chemical structure is 4-morpholinecarboxylic acid, 2-((2-(4-(aminosulfonyl)-2,6-difluorophenyl)-7-chloroimidazo(1,2-b)pyridazin-6-yl)amino)-3-pyridinecarboxylic acid, and it is available for research use.[1][3][5][8][9][11]